Check out what we have in store for you in the February Mid-Month Newsletter
There is a whole lot of shaking going on in the wide world of hepatitis C!
In the mid-month edition of the February 2016 HCV Advocate newsletter we have the following news articles:
- HCV Drugs: January ended with the approval of Zepatier—a once-a-day pill to treat HCV genotype 1 and 4 with cure rates from 90 to 100%. Also, February started with the approval of Daklinza in combination with sofosbuvir in HIV and HCV coinfection, people with advanced HCV disease progression and for treatment of HCV recurrence after liver transplantation.
- Snapshots: This month’s issue has three studies—treating cryoglobulinemia with direct-acting antivirals, the incidence of cirrhosis in the diagnosed and undiagnosed, and a review of HCV and mother-to-child transmission.
- Cryoglobulinemia: An overview of the disease and the consequences.
- HCV Advocate Drug Pipeline: We have linked the Gilead information from ASTRAL studies to the section in the pipeline under the Gilead section.
Easy C Treatment Guide – Genotype 1 – A simple guide to current treatments for genotype 1:
- Viekira Pak
The guide is the first in a series of treatment guides by genotype.
Extrahepatic Manifestation Glossary – A new glossary about diseases linked to hepatitis C or that are seen more frequently in people infected with the hepatitis C virus.